Dexmedetomidine Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Dexmedetomidine
Therapeutic Class: Sedative-hypnotic
Subclass: Selective alpha-2 adrenoceptor agonist
Speciality: Anaesthesiology
Schedule (India): Schedule H
Route(s): Intravenous (IV), Intramuscular (off-label, rarely used)
Formulations Available in India:
- Concentrate for injection: 100 mcg/mL in 2 mL ampoule/vial
- Premixed infusion (select brands): 200 mcg/50 mL (4 mcg/mL)
- Premixed infusion (select brands): 400 mcg/100 mL (4 mcg/mL)
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶ 1. ICU Sedation in Mechanically Ventilated Patients (up to 24 hours)
| Parameter | Recommendation |
|---|---|
|
Starting dose
|
1 mcg/kg IV over 10 minutes (loading dose — optional in haemodynamically unstable patients) |
|
Titration
|
Adjust by 0.1 mcg/kg/hour every 15–30 minutes to achieve RASS -1 to 0 |
|
Usual maintenance dose
|
0.2–0.7 mcg/kg/hour IV infusion |
|
Maximum dose
|
1.4 mcg/kg/hour (higher doses not recommended routinely) |
Clinical Notes:
- Avoid loading dose in patients with hypotension, bradycardia, or haemodynamic instability
- Preferred sedation target: RASS -1 to 0 for light sedation
- Allows patient interaction and neurological assessment during sedation
▶ 2. Sedation for Procedural Interventions (e.g., fibreoptic intubation, awake craniotomy, minor procedures)
| Parameter | Recommendation |
|---|---|
|
Starting dose
|
1 mcg/kg IV over 10 minutes (may omit bolus in elderly or hypotensive patients) |
|
Titration
|
Adjust based on procedural requirements and patient response |
|
Usual maintenance dose
|
0.2–1 mcg/kg/hour IV infusion |
|
Maximum dose
|
1 mcg/kg/hour |
Clinical Notes:
- Provides conscious sedation without significant respiratory depression
- Ideal for awake intubation procedures requiring patient cooperation
- Titrate closely; patient should remain rousable to verbal stimuli
Secondary Indications — Adults Only (Off-label)
| Indication | Dosing | Duration | Notes |
|---|---|---|---|
|
Perioperative sedation (cardiac/high-risk surgery) — OFF-LABEL
|
Starting dose: 0.5–1 mcg/kg IV over 10–20 min; Titration: Based on haemodynamic response; Usual maintenance: 0.2–0.7 mcg/kg/hour; Maximum: 1 mcg/kg/hour | Until end of surgery or extubation | Specialist only. Evidence: Indian cardiac centres, RCTs demonstrating haemodynamic stability benefits |
|
Adjunct to regional anaesthesia (spinal/epidural/nerve blocks) — OFF-LABEL
|
IV route: 0.5–1 mcg/kg single dose; Perineural route: 1–2 mcg/kg added to local anaesthetic | Procedural duration | Specialist only. Evidence: Indian anaesthesia practice, RCTs showing prolonged block duration, opioid-sparing effect |
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
▶ ICU Sedation in Ventilated Children (>1 month of age) — SPECIALIST USE ONLY
| Parameter | Recommendation |
|---|---|
|
Starting dose
|
0.5–1 mcg/kg IV over 10 minutes (loading dose — optional) |
|
Titration
|
Adjust by 0.1–0.2 mcg/kg/hour every 15–30 minutes based on sedation score |
|
Usual maintenance dose
|
0.2–1 mcg/kg/hour IV infusion |
|
Maximum dose
|
1 mcg/kg/hour |
Clinical Notes:
- Titrate to target COMFORT or RASS score
- Monitor HR, BP, and peripheral perfusion closely
- Avoid in children with pre-existing bradycardia or conduction defects
Secondary Indications — Paediatrics (Off-label)
| Indication | Dosing | Duration | Notes |
|---|---|---|---|
|
Procedural sedation (MRI, minor procedures) — OFF-LABEL
|
Starting dose: 1–2 mcg/kg IV over 10 min; Usual maintenance: 0.5–1 mcg/kg/hour; Maximum: 1.5 mcg/kg/hour | Until procedure ends | Specialist only (paediatric anaesthesia or PICU setting). Evidence: Indian tertiary centre protocols; favourable respiratory profile |
Safety Monitoring (Paediatric):
- Continuous ECG, HR, and BP monitoring mandatory
- Pulse oximetry throughout procedure
- Age >1 month required; neonates (<1 month) only under NICU specialist protocol with extreme caution
Age Restrictions:
- Not recommended below 1 month of age except under neonatal ICU specialist supervision
RENAL ADJUSTMENT
| Renal Function | Recommendation |
|---|---|
| Mild–Moderate–Severe impairment | No dosage adjustment required |
| Haemodialysis | Use with caution — delayed clearance may prolong sedation; monitor closely |
| Peritoneal dialysis | No specific data; monitor for prolonged effects |
HEPATIC ADJUSTMENT
| Severity | Recommendation |
|---|---|
|
Mild impairment
|
Start at lower maintenance rate (0.2 mcg/kg/hour); titrate cautiously based on response |
|
Moderate impairment
|
Reduce maintenance rate by approximately 50%; monitor for prolonged sedation |
|
Severe impairment
|
Avoid if possible; high risk of drug accumulation; use only under specialist supervision with close monitoring |
CONTRAINDICATIONS
- Known hypersensitivity to dexmedetomidine or any excipient
- Advanced heart block (2nd or 3rd degree) without functional pacemaker
- Severe ventricular dysfunction with uncontrolled hypotension
- Acute cerebrovascular event with haemodynamic instability
- Uncontrolled bradycardia (HR <50/min)
CAUTIONS
- Elderly patients — increased sensitivity to hypotensive and bradycardic effects
- Volume-depleted or hypovolaemic patients — augmented hypotensive response
- Concurrent use of vasodilators, beta-blockers, or other negative chronotropes
- Pre-existing cardiac conduction abnormalities (1st degree AV block)
- Hypoxia — may exacerbate bradycardia
- Avoid rapid IV bolus administration — risk of transient severe hypertension followed by bradycardia
- Prolonged infusion (>24 hours) — risk of withdrawal syndrome on abrupt discontinuation
PREGNANCY
| Aspect | Details |
|---|---|
|
Overall safety
|
Limited human data; crosses placenta |
|
When to use
|
Only if clearly indicated and benefit outweighs risk; specialist decision required |
|
Preferred alternatives
|
Midazolam (short-term sedation), Propofol (perioperative use) |
|
Monitoring required
|
Maternal haemodynamics (HR, BP); fetal heart rate monitoring if used peri-delivery |
LACTATION
| Aspect | Details |
|---|---|
|
Compatibility
|
Compatible with breastfeeding; minimal excretion in breast milk reported |
|
Expected levels in milk
|
Low |
|
Preferred alternatives
|
Shorter-acting sedatives (e.g., midazolam) when feasible |
|
Infant monitoring
|
Monitor for drowsiness, feeding difficulty, hypotonia |
ELDERLY
| Aspect | Recommendation |
|---|---|
|
Starting dose
|
50% lower than standard adult dose; start maintenance at 0.1–0.3 mcg/kg/hour |
|
Titration
|
Slower titration at 0.1 mcg/kg/hour increments |
|
Extra risks
|
Exaggerated bradycardia, hypotension, prolonged sedation, falls (post-procedure) |
|
Monitoring
|
Enhanced sensitivity to alpha-2 agonists; continuous vital signs monitoring essential |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect/Risk | Management |
|---|---|---|
|
Beta-blockers (metoprolol, esmolol, carvedilol)
|
Additive risk of severe bradycardia and hypotension | Avoid combination or reduce doses of both; continuous monitoring required |
|
Clonidine
|
Enhanced alpha-2 agonist effects; excessive sedation and bradycardia | Avoid concomitant use |
|
Other anaesthetics (propofol, ketamine, opioids)
|
Synergistic CNS depression | Reduce doses of co-administered anaesthetics by 25–50%; titrate carefully |
|
Digoxin
|
Additive bradycardia | Monitor HR closely; consider dose reduction |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect/Risk | Management |
|---|---|---|
|
Calcium-channel blockers (verapamil, diltiazem, amlodipine)
|
Additive hypotension and bradycardia | Monitor BP and HR; adjust doses as needed |
|
Opioids (fentanyl, morphine)
|
Potentiation of sedation; enhanced analgesia | Use for opioid-sparing effect; reduce opioid dose by 30–50% |
|
Antipsychotics (haloperidol, risperidone)
|
Additive QT prolongation risk; bradycardia | Monitor ECG; avoid in patients with baseline QT prolongation |
|
Antihypertensives
|
Enhanced hypotensive effect | Ensure adequate hydration; monitor BP closely |
COMMON ADVERSE EFFECTS
- Bradycardia (15–40%)
- Hypotension (up to 30%)
- Dry mouth
- Nausea
- Over-sedation (dose-related)
- Fever (especially in paediatric population)
- Transient hypertension during loading dose
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Notes |
|---|---|
| Severe bradycardia or asystole | Requires immediate drug cessation; atropine, glycopyrrolate, or temporary pacing may be needed |
| Profound hypotension | Fluid resuscitation; vasopressor support may be required |
| Withdrawal hypertension | Occurs with abrupt discontinuation after prolonged infusion (>24–48 hours); taper dose |
| Respiratory depression | Rare in monotherapy; occurs mainly with concomitant CNS depressants; ensure airway management available |
| Sinus arrest | Rare; discontinue immediately if occurs |
MONITORING REQUIREMENTS
| Timing | Parameters |
|---|---|
|
Baseline
|
Heart rate, blood pressure, ECG (especially if cardiac history), volume status assessment, hepatic function |
|
During initiation/dose change
|
Continuous ECG and BP monitoring during loading dose and first 1–2 hours; pulse oximetry; sedation scoring (RASS/COMFORT) |
|
Long-term (if >24 hours)
|
Hepatic function if abnormality suspected; monitor for withdrawal symptoms on tapering; reassess sedation goals daily |
BRANDS AVAILABLE IN INDIA
- Dexem (Themis Medicare)
- Dexogin (Neon Laboratories)
- Dextomid (Intas Pharmaceuticals)
- Precedex (Pfizer/Abbott)
- Dexmid (Cipla)
- Dexdom (Sun Pharma)
Note: "Dexona" by some manufacturers refers to dexamethasone — verify prescription carefully to avoid dispensing errors.
PRICE RANGE (INR)
| Formulation | Price Range | Notes |
|---|---|---|
| 100 mcg/mL (2 mL ampoule) | ₹300–₹600 per ampoule | Brand-dependent variation |
| Premixed infusion (200 mcg/50 mL) | ₹500–₹900 per bag | Limited availability |
- Some formulations NPPA-controlled under NLEM for ICU sedation
- Government procurement prices may be significantly lower
CLINICAL PEARLS
- Unique advantage: Provides sedation without significant respiratory depression — ideal for difficult airway management and ICU weaning protocols.
- Avoid rapid bolus administration — slow loading over 10 minutes prevents dangerous bradycardia and transient hypertension.
- Bradycardia management: Keep atropine or glycopyrrolate ready during loading dose; avoid in patients with baseline HR <60/min without pacemaker.
- Opioid-sparing strategy: Reduces opioid requirements by 30–50% when used as adjunct in ICU or perioperative setting.
- Taper after prolonged use: Do not stop abruptly after >24–48 hours of infusion — gradual dose reduction prevents rebound hypertension and agitation.
- Elderly dosing: Start at half the usual rate (0.1–0.3 mcg/kg/hour) — enhanced sensitivity to alpha-2 agonists in this population.
TAGS
dexmedetomidine; sedation; ICU; procedural sedation; alpha-2 agonist; bradycardia risk; mechanically ventilated; anaesthesia; NLEM India; Schedule H
VERSION
RxIndia v0.9 — 18 Feb 2026
REFERENCES
- CDSCO injection approvals
- Indian Pharmacopoeia 2018
- NLEM India
- AIIMS Adult Sedation Protocol
- API Textbook of Medicine, 11th edition
- ICMR Guidelines for ICU Care (sedation protocols)
- Indian Journal of Anaesthesia (RCTs on paediatric and procedural use — for off-label evidence)
- WHO Essential Medicines List (supportive for paediatric indications)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.